JAMA Report Investigates Cost-effectiveness Studies for Cancer Drugs

January 6, 2022

In a new article in the Journal of the American Medical Association, researchers Alyson Haslam, PhD, Mark P. Lythgoe, MD, and Emma Greenstreet Akman, et al. probe 228 cost-effectiveness studies, 116 drug approvals, and 254 analyses. Upon investigation, studies funded by pharmaceutical companies were 40 times more likely to declare a drug cost-effective than those with no funding from pharma.

According to the authors, “In this analysis of cost-effectiveness studies on oncology drugs, we found that the largest factor associated with whether a drug was found to be cost-effective was if the study was funded by the pharmaceutical industry. This factor was associated with positive cost-effectiveness findings even when considering therapeutic or clinical outcomes (eg, OS or PFS).”

Read the open-access paper by clicking here.

(Source: JAMA Network Open, November 18th, 2021)

Share This Story!